Table 2
Open in new tab

Expected ranges of NOAC plasma levels by dose and clinical indication

MoleculeTestPeak54,55DoseIndicationTrough/peakPlasma level (ng/mL)Ref.
Dabigatran20,56dTT1.5–3 h150 mg bidAFTrough91 (25–75th percentile: 61–143)SPC
Peak175 (25–75th percentile: 117–275)SPC
VTETrough60 (25–75th percentile: 39–95)SPC
Peak175 (25–75th percentile: 117–275)SPC
110 mg bidAFTrough63 (5–95th percentile: 62–64)34
PeakNo data found
VTETroughNo data found
PeakNo data found
Rivaroxaban19,57,58Chromogene anti-FXA assay2–3 h20 mg odAFTrough44 (5–95th percentile: 22–137)19
Peak249 (5–95th percentile: 184–343)19
VTETrough26 (5–95th percentile: 6–87)19
Peak270 (5–95th percentile: 189–419)19
15 mg odAFTrough57 (5–95th percentile: 18–136)19
Peak229 (5–95th percentile: 178–313)19
10 mg odVTE prevention after joint surgeryTrough9 (5–95th percentile: 1–38)19
Peak125 (5–95th percentile: 91–196)19
10 mg odVTE secondary preventionTrough14 (min/max: 4–51)SPC
10 mg odVTE secondary preventionPeak101 (min/max: 7–273)SPC
2.5 mg bidVascular prevention in chronic CAD/PADTrough17 (5–95th percentile: 6–37)19
Peak46 (5–95th percentile: 28–70)19
Apixaban16,17,59–61Chromogene anti-FXA assay3–4 h5 mg bidAFTrough103 (5–95th percentile: 41–230)SPC17
Peak171 (5–95th percentile: 91–321)SPC17
10 mg bidVTE (initial treatment)Trough120 (5–95th percentile: 41–335)SPC17
Peak251 (5–95th percentile: 111–572)SPC17
5 mg bidVTETrough63 (5–95th percentile: 22–177)SPC17
Peak132 (5–95th percentile: 59–302)SPC17
2.5 mg bidAFTrough79 (5–95th percentile: 34–162)SPC17
Peak123 (5–95th percentile: 69–221)SPC17
VTETrough32 (5–95th percentile: 11–90)SPC17
Peak67 (5–95th percentile: 153)SPC17
Edoxaban62Chromogene anti-FXA assay1–2 h60 mg odAFTrough36 (25–75th percentile: 19–62)63
Peak170 (1.5*IQR125–245)27
VTETrough19 (25–75th percentile: 10–39)64
Peak234 (25–75th percentile: 149–317)64
30 mg odAFTrough27 (25–75th percentile: 15–44.6)63
Peak85 (57–115)27
VTETrough16 (25–75th percentile: 8–32)64
Peak164 (25–75th percentile: 99–225)64
15 mg odAFTrough12 (25–75th percentile: 7–21)63
PeakNo data found
MoleculeTestPeak54,55DoseIndicationTrough/peakPlasma level (ng/mL)Ref.
Dabigatran20,56dTT1.5–3 h150 mg bidAFTrough91 (25–75th percentile: 61–143)SPC
Peak175 (25–75th percentile: 117–275)SPC
VTETrough60 (25–75th percentile: 39–95)SPC
Peak175 (25–75th percentile: 117–275)SPC
110 mg bidAFTrough63 (5–95th percentile: 62–64)34
PeakNo data found
VTETroughNo data found
PeakNo data found
Rivaroxaban19,57,58Chromogene anti-FXA assay2–3 h20 mg odAFTrough44 (5–95th percentile: 22–137)19
Peak249 (5–95th percentile: 184–343)19
VTETrough26 (5–95th percentile: 6–87)19
Peak270 (5–95th percentile: 189–419)19
15 mg odAFTrough57 (5–95th percentile: 18–136)19
Peak229 (5–95th percentile: 178–313)19
10 mg odVTE prevention after joint surgeryTrough9 (5–95th percentile: 1–38)19
Peak125 (5–95th percentile: 91–196)19
10 mg odVTE secondary preventionTrough14 (min/max: 4–51)SPC
10 mg odVTE secondary preventionPeak101 (min/max: 7–273)SPC
2.5 mg bidVascular prevention in chronic CAD/PADTrough17 (5–95th percentile: 6–37)19
Peak46 (5–95th percentile: 28–70)19
Apixaban16,17,59–61Chromogene anti-FXA assay3–4 h5 mg bidAFTrough103 (5–95th percentile: 41–230)SPC17
Peak171 (5–95th percentile: 91–321)SPC17
10 mg bidVTE (initial treatment)Trough120 (5–95th percentile: 41–335)SPC17
Peak251 (5–95th percentile: 111–572)SPC17
5 mg bidVTETrough63 (5–95th percentile: 22–177)SPC17
Peak132 (5–95th percentile: 59–302)SPC17
2.5 mg bidAFTrough79 (5–95th percentile: 34–162)SPC17
Peak123 (5–95th percentile: 69–221)SPC17
VTETrough32 (5–95th percentile: 11–90)SPC17
Peak67 (5–95th percentile: 153)SPC17
Edoxaban62Chromogene anti-FXA assay1–2 h60 mg odAFTrough36 (25–75th percentile: 19–62)63
Peak170 (1.5*IQR125–245)27
VTETrough19 (25–75th percentile: 10–39)64
Peak234 (25–75th percentile: 149–317)64
30 mg odAFTrough27 (25–75th percentile: 15–44.6)63
Peak85 (57–115)27
VTETrough16 (25–75th percentile: 8–32)64
Peak164 (25–75th percentile: 99–225)64
15 mg odAFTrough12 (25–75th percentile: 7–21)63
PeakNo data found
Table 2
Open in new tab

Expected ranges of NOAC plasma levels by dose and clinical indication

MoleculeTestPeak54,55DoseIndicationTrough/peakPlasma level (ng/mL)Ref.
Dabigatran20,56dTT1.5–3 h150 mg bidAFTrough91 (25–75th percentile: 61–143)SPC
Peak175 (25–75th percentile: 117–275)SPC
VTETrough60 (25–75th percentile: 39–95)SPC
Peak175 (25–75th percentile: 117–275)SPC
110 mg bidAFTrough63 (5–95th percentile: 62–64)34
PeakNo data found
VTETroughNo data found
PeakNo data found
Rivaroxaban19,57,58Chromogene anti-FXA assay2–3 h20 mg odAFTrough44 (5–95th percentile: 22–137)19
Peak249 (5–95th percentile: 184–343)19
VTETrough26 (5–95th percentile: 6–87)19
Peak270 (5–95th percentile: 189–419)19
15 mg odAFTrough57 (5–95th percentile: 18–136)19
Peak229 (5–95th percentile: 178–313)19
10 mg odVTE prevention after joint surgeryTrough9 (5–95th percentile: 1–38)19
Peak125 (5–95th percentile: 91–196)19
10 mg odVTE secondary preventionTrough14 (min/max: 4–51)SPC
10 mg odVTE secondary preventionPeak101 (min/max: 7–273)SPC
2.5 mg bidVascular prevention in chronic CAD/PADTrough17 (5–95th percentile: 6–37)19
Peak46 (5–95th percentile: 28–70)19
Apixaban16,17,59–61Chromogene anti-FXA assay3–4 h5 mg bidAFTrough103 (5–95th percentile: 41–230)SPC17
Peak171 (5–95th percentile: 91–321)SPC17
10 mg bidVTE (initial treatment)Trough120 (5–95th percentile: 41–335)SPC17
Peak251 (5–95th percentile: 111–572)SPC17
5 mg bidVTETrough63 (5–95th percentile: 22–177)SPC17
Peak132 (5–95th percentile: 59–302)SPC17
2.5 mg bidAFTrough79 (5–95th percentile: 34–162)SPC17
Peak123 (5–95th percentile: 69–221)SPC17
VTETrough32 (5–95th percentile: 11–90)SPC17
Peak67 (5–95th percentile: 153)SPC17
Edoxaban62Chromogene anti-FXA assay1–2 h60 mg odAFTrough36 (25–75th percentile: 19–62)63
Peak170 (1.5*IQR125–245)27
VTETrough19 (25–75th percentile: 10–39)64
Peak234 (25–75th percentile: 149–317)64
30 mg odAFTrough27 (25–75th percentile: 15–44.6)63
Peak85 (57–115)27
VTETrough16 (25–75th percentile: 8–32)64
Peak164 (25–75th percentile: 99–225)64
15 mg odAFTrough12 (25–75th percentile: 7–21)63
PeakNo data found
MoleculeTestPeak54,55DoseIndicationTrough/peakPlasma level (ng/mL)Ref.
Dabigatran20,56dTT1.5–3 h150 mg bidAFTrough91 (25–75th percentile: 61–143)SPC
Peak175 (25–75th percentile: 117–275)SPC
VTETrough60 (25–75th percentile: 39–95)SPC
Peak175 (25–75th percentile: 117–275)SPC
110 mg bidAFTrough63 (5–95th percentile: 62–64)34
PeakNo data found
VTETroughNo data found
PeakNo data found
Rivaroxaban19,57,58Chromogene anti-FXA assay2–3 h20 mg odAFTrough44 (5–95th percentile: 22–137)19
Peak249 (5–95th percentile: 184–343)19
VTETrough26 (5–95th percentile: 6–87)19
Peak270 (5–95th percentile: 189–419)19
15 mg odAFTrough57 (5–95th percentile: 18–136)19
Peak229 (5–95th percentile: 178–313)19
10 mg odVTE prevention after joint surgeryTrough9 (5–95th percentile: 1–38)19
Peak125 (5–95th percentile: 91–196)19
10 mg odVTE secondary preventionTrough14 (min/max: 4–51)SPC
10 mg odVTE secondary preventionPeak101 (min/max: 7–273)SPC
2.5 mg bidVascular prevention in chronic CAD/PADTrough17 (5–95th percentile: 6–37)19
Peak46 (5–95th percentile: 28–70)19
Apixaban16,17,59–61Chromogene anti-FXA assay3–4 h5 mg bidAFTrough103 (5–95th percentile: 41–230)SPC17
Peak171 (5–95th percentile: 91–321)SPC17
10 mg bidVTE (initial treatment)Trough120 (5–95th percentile: 41–335)SPC17
Peak251 (5–95th percentile: 111–572)SPC17
5 mg bidVTETrough63 (5–95th percentile: 22–177)SPC17
Peak132 (5–95th percentile: 59–302)SPC17
2.5 mg bidAFTrough79 (5–95th percentile: 34–162)SPC17
Peak123 (5–95th percentile: 69–221)SPC17
VTETrough32 (5–95th percentile: 11–90)SPC17
Peak67 (5–95th percentile: 153)SPC17
Edoxaban62Chromogene anti-FXA assay1–2 h60 mg odAFTrough36 (25–75th percentile: 19–62)63
Peak170 (1.5*IQR125–245)27
VTETrough19 (25–75th percentile: 10–39)64
Peak234 (25–75th percentile: 149–317)64
30 mg odAFTrough27 (25–75th percentile: 15–44.6)63
Peak85 (57–115)27
VTETrough16 (25–75th percentile: 8–32)64
Peak164 (25–75th percentile: 99–225)64
15 mg odAFTrough12 (25–75th percentile: 7–21)63
PeakNo data found
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close